Trials / Completed
CompletedNCT02516579
European Sickle Cell Disease Cohort - Hydroxyurea
ESCORT-HU : European Sickle Cell Disease Cohort - Hydroxyurea
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,906 (actual)
- Sponsor
- Theravia · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
In the context of the Risk Management Plan (RMP), as requested from Addmedica by the EMEA, to collect information about long-term safety of Siklos® (hydroxycarbamide) when used in patients with Sickle Cell Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Siklos |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2019-03-20
- Completion
- 2019-03-20
- First posted
- 2015-08-06
- Last updated
- 2020-03-19
- Results posted
- 2020-03-19
Locations
60 sites across 7 countries: France, French Guiana, Germany, Greece, Guadeloupe, Italy, Martinique
Source: ClinicalTrials.gov record NCT02516579. Inclusion in this directory is not an endorsement.